If we are to develop an NGF-based therapeutic strategy for AD, it is important that we strive to understand the mechanisms that are responsible for the deregulation of proNGF/NGF processing, particularly with regard to the reduction of tPA or plasmin. The gene discussed is PLAT; the disease is Alzheimer disease.